

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG ID6454

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
Company	<u>General</u>
Pfizer (Sasanlimab with BCG)	All Wales Therapeutics and Toxicology
B .:	Centre
Patient/carer groups	Allied Health Professionals Federation
Action Bladder Cancer UKBlack Health Agency for Equality	 Board of Community Health Councils in Wales
DI 11 15 10 11	
DI 11 15 1111/	British National Formulary Care Quality Commission
_	Care Quality Commission Parastraort of Haalth, Conicl Commission
Cancer Black Care Cancer Black Care	Department of Health, Social Services And Bubble Sefety for Northern Indian
Fight Bladder Cancer	and Public Safety for Northern Ireland
Independent Cancer Patients Voice	Healthcare Improvement Scotland
Kidney Cancer UK	Medicines and Healthcare products
Kidney Care	Regulatory Agency
Kidney Research UK	National Association of Primary Care
Kidney Patient Involvement Network	National Pharmacy Association
Macmillan Cancer Support	NHS Confederation
Maggie's Centres	NHS Wales Joint Commissioning
Marie Curie	Committee
 National Kidney Federation 	Scottish Medicines Consortium
 South Asian Health Foundation 	Welsh Government
Specialised Healthcare Alliance	
Tenovus Cancer Care	Possible comparator companies
	AJ Vaccines A/S (BCG)
Healthcare professional groups	Medac Pharma (BCG)
Association of Cancer Physicians	Merck Sharpe & Dohme (BCG)
British Association of Urological	
Nurses	Relevant research groups
British Association of Urological	Cochrane Urology
Surgeons	Genomics England
British Geriatrics Society	Institute of Cancer Research
British Institute of Radiology	MRC Clinical Trials Unit
British Oncology Pharmacy	National Institute for Health Research
Association	
British Psychosocial Oncology Society	Associated Public Health groups
British Society of Urogenital Radiology	Public Health Wales

Provisional stakeholder list for the evaluation of sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG Issue date: November 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Society of Urogynaecology British Uro-Oncology Group Cancer Research UK Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Urology Foundation 	UK Health Security Agency
OthersDepartment of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG Issue date: November 2025



Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.